These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20482871)

  • 21. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High level of Sema3C is associated with glioma malignancy.
    Vaitkienė P; Skiriutė D; Steponaitis G; Skauminas K; Tamašauskas A; Kazlauskas A
    Diagn Pathol; 2015 Jun; 10():58. PubMed ID: 26032848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
    Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
    J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diet and risk of adult glioma in eastern Nebraska, United States.
    Chen H; Ward MH; Tucker KL; Graubard BI; McComb RD; Potischman NA; Weisenburger DD; Heineman EF
    Cancer Causes Control; 2002 Sep; 13(7):647-55. PubMed ID: 12296512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and low-grade glioma: the emergence of genetic information.
    Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
    Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
    Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
    Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma.
    Hu L; Lv QL; Chen SH; Sun B; Qu Q; Cheng L; Guo Y; Zhou HH; Fan L
    Int J Environ Res Public Health; 2016 Apr; 13(4):433. PubMed ID: 27104549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Survival of newly diagnosed malignant glioma patients on combined modality therapy].
    Yang QY; Shen D; Sai K; Jiang XB; Ke C; Zhang XH; Mou YG; Chen ZP
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):8-10. PubMed ID: 23578444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF2 as a potential prognostic biomarker for proneural glioma patients.
    Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
    Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
    Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
    Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
    Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
    J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
    Liu H; Liu B; Hou X; Pang B; Guo P; Jiang W; Ding Q; Zhang R; Xin T; Guo H; Xu S; Pang Q
    J Neurooncol; 2017 May; 132(3):409-417. PubMed ID: 28321704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.
    Claus EB; Black PM
    Cancer; 2006 Mar; 106(6):1358-63. PubMed ID: 16470608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
    Lote K; Egeland T; Hager B; Stenwig B; Skullerud K; Berg-Johnsen J; Storm-Mathisen I; Hirschberg H
    J Clin Oncol; 1997 Sep; 15(9):3129-40. PubMed ID: 9294476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low expression of miR-1231 in patients with glioma and its prognostic significance.
    Wang H; Wu J; Luo WJ; Hu JL
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8399-8405. PubMed ID: 30556881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
    Wu W; Lamborn KR; Buckner JC; Novotny PJ; Chang SM; O'Fallon JR; Jaeckle KA; Prados MD
    Neuro Oncol; 2010 Feb; 12(2):164-72. PubMed ID: 20150383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term prognostic assessment of 185 newly diagnosed gliomas: Grade III glioma showed prognosis comparable to that of Grade II glioma.
    Shinohara C; Muragaki Y; Maruyama T; Shimizu S; Tanaka M; Kubota Y; Oikawa M; Nakamura R; Iseki H; Kubo O; Takakura K; Hori T
    Jpn J Clin Oncol; 2008 Nov; 38(11):730-3. PubMed ID: 18820008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.
    Jhaveri J; Liu Y; Chowdhary M; Buchwald ZS; Gillespie TW; Olson JJ; Voloschin AD; Eaton BR; Shu HG; Crocker IR; Curran WJ; Patel KR
    Cancer; 2018 Mar; 124(6):1169-1178. PubMed ID: 29205287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.